» Authors » Philip E Tarr

Philip E Tarr

Explore the profile of Philip E Tarr including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 107
Citations 1339
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Riebensahm C, Brocker J, Berzigotti A, Gunthard H, Tarr P, Furrer H, et al.
Open Forum Infect Dis . 2024 Sep; 11(9):ofae411. PMID: 39282634
Background: Fatty liver index (FLI) and hepatic steatosis index (HSI) are serologic scores used to detect liver steatosis. However, their diagnostic performance in people with HIV (PWH) remains unclear. We...
2.
Rupasinghe D, Bansi-Matharu L, Law M, Zangerle R, Rauch A, Tarr P, et al.
Clin Infect Dis . 2024 Aug; 80(2):404-416. PMID: 39117341
Background: With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases associated with higher diabetes mellitus (DM) risk, we explored the relationships between...
3.
Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr P, et al.
Clin Infect Dis . 2024 Apr; 79(4):990-998. PMID: 38606792
Background: Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about...
4.
Luthi-Corridori G, Roth A, Boesing M, Jaun F, Tarr P, Leuppi-Taegtmeyer A, et al.
J Clin Med . 2024 Jan; 13(2). PMID: 38276080
Background: Despite advances in therapy, community-acquired pneumonia (CAP) is still associated with significant morbidity and mortality. Several studies conducted in different countries have reported suboptimal adherence to the guidelines. However,...
5.
Riebensahm C, Berzigotti A, Surial B, Haerry D, Gunthard H, Tarr P, et al.
J Acquir Immune Defic Syndr . 2023 Nov; 95(2):179-184. PMID: 37988659
Background: Physical activity (PA) regulates intrahepatic storage of fat and reduces the risk of liver steatosis. Given our limited understanding of the pathogenesis of metabolic complications in people with HIV...
6.
Hovaguimian F, Kouyos R, Kusejko K, Schmidt A, Tarr P, Bernasconi E, et al.
HIV Med . 2023 Sep; 25(1):117-128. PMID: 37771207
Objectives: Our objective was to obtain long-term data on the incidence of sexually transmitted infections (STIs) and their association with behavioural factors after widespread pre-exposure prophylaxis (PrEP) implementation. Methods: This...
7.
Zimmermann C, Jusufoska M, Tolic J, Abreu de Azevedo M, Tarr P, Deml M
BMJ Open . 2023 Sep; 13(9):e074883. PMID: 37696631
Background: Many community pharmacies in Switzerland provide complementary and alternative medicine (CAM) approaches in addition to providing biomedical services, and a few pharmacies specialise in CAM. A common perception is...
8.
Berton M, Bettonte S, Stader F, Decosterd L, Tarr P, Livio F, et al.
Clin Infect Dis . 2023 Aug; 78(1):98-110. PMID: 37602428
Background: Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given...
9.
Schwenke J, Thorball C, Schoepf I, Ryom L, Hasse B, Lamy O, et al.
J Infect Dis . 2023 May; 228(6):742-750. PMID: 37225667
Background: Bone mineral density (BMD) loss may be accelerated in people with HIV (PLWH). It is unknown whether a polygenic risk score (PRS) is associated with low BMD in PLWH....
10.
Surial B, Chammartin F, Damas J, Calmy A, Haerry D, Stockle M, et al.
Clin Infect Dis . 2023 May; 77(5):729-737. PMID: 37157869
Background: Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD...